Time to AIDS from 1992 to 1999 in HIV-1-Infected Subjects with Known Date of Infection.
AffiliationInstitut National de la Santé et de la Recherche Médicale SC4, Faculté de Médecine, St. Antoine Université Pierre et Marie Curie, Paris, France; Epicentre, Paris, France.
MetadataShow full item record
AbstractTo estimate the change in AIDS incubation time during three periods characterized by different availability of antiretroviral treatments, data from the French Hospital Database on HIV of 4702 HIV-1-positive subjects with a documented date of infection were analyzed. Times from seroconversion to AIDS were compared in three periods: period 1 from January 1992 to June 1995 (monotherapy); period 2 from July 1995 to June 1996 (dual therapy); and period 3 from July 1996 to June 1999 (triple therapy). Nonparametric survival analyses were performed to account for staggered entries in the database and during each period. From periods 1 to 3, antiretroviral treatments were initiated earlier after infection, more subjects were treated, and the nature of regimens changed (25.6% of subjects were treated with monotherapy in period 1, 34.6% were treated with dual therapy in period 2, and 53.4% were treated with triple therapy in period 3). Compared with period 1, the relative hazard (RH) of AIDS was 0.31 in period 3 (95% confidence interval [CI]: 0.24-0.39). When comparing period 3 with period 2, the RH of AIDS was 0.36 (CI: 0.29-0.45). Assuming a log normal distribution, the median time to AIDS was estimated as 8.0 years in period 1 (CI: 6.0-10.6), 9.8 years in period 2 (CI: 8.5, 11.2), and 20.0 years in period 3 (CI: 17.1-23.3). This lengthening in time to AIDS from 1992 to 1999 was particularly marked in the period after the introduction of triple therapy, including protease inhibitors.
- Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV.
- Authors: Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boué F, Billaud E, Costagliola D
- Issue date: 1999 Oct 1
- Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
- Authors: Alioum A, Leroy V, Commenges D, Dabis F, Salamon R
- Issue date: 1998 Nov
- Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?
- Authors: Rancinan C, Neau D, Savès M, Lawson-Ayayi S, Bonnet F, Mercié P, Dupon M, Couzigou P, Dabis F, Chêne G, Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
- Issue date: 2002 Jul 5
- [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
- Authors: Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G, l'Italian Seroconversion Study.
- Issue date: 2003 Nov-Dec
- Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
- Authors: Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J, PISCIS Study Group.
- Issue date: 2008 Feb 1